-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol Therapeutics expands Phase III MAVERIC trial to up to 150 patients for CardiolRx in recurrent pericarditis

PUBT·09/23/2026 10:02:04
Cardiol Therapeutics expands Phase III MAVERIC trial to up to 150 patients for CardiolRx in recurrent pericarditis
  • Cardiol Therapeutics expanded its Phase III MAVERIC trial of CardiolRx in recurrent pericarditis to up to 150 patients.
  • The original 110-patient enrollment target was reached ahead of the end-of-September timetable.
  • A blinded review showed fewer recurrences than expected, prompting the expansion to support a clearer efficacy readout.
  • Topline results have not been presented yet; the company now expects them in mid-2027, later than prior Q1 2027 guidance.
  • Management expects existing capital to fund completion, extending cash runway into Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609230600CANADANWCANADAPR_C2617) on September 23, 2026, and is solely responsible for the information contained therein.